Colin A. Baron, MBA
PARTNER AND MANAGING DIRECTOR
Drawing on over 15 years experience in genomics discovery and translational research, Colin co-founded Chrysalis Biomedical Advisors in 2016. Prior to Chrysalis, Colin served as Senior Director, Head of Global Product Management at QIAGEN and was responsible for driving development, commercial strategy, and marketing for Next Generation Sequencing and Single Cell platforms.
Previously, Colin held numerous positions at Illumina, joining the former Solexa team shortly after its acquisition. During his 6-year tenure, he managed the company’s NGS sequencing chemistry portfolio and led over 35 major sequencing platform launches, ranging from the the Genome Analyzer II to the NextSeq and HiSeq X10 systems. He also designed and developed Clinical & Translational products for Illumina’s BeadXpress Diagnostic platform, as well as Illumina’s premium line of LDT-focused sequencing products.
Prior to Illumina, Colin held several Academic Core Lab management positions at UC Davis, including bioinformatics analysis and clinical tissue and serum biobanking for an NCI-designated Biobank. Colin graduated from UC Davis in 2001 with a double major in Microbiology and Economics. He earned his MBA from the UC Davis Graduate School of Management in 2008.
Colin is an avid traveler, enjoys British dramatic theatre, and loves having his German pronunciation corrected by his 3 year old son.
ROBERT D. COHEN, MBA
Partner and Managing Director
Rob has been in the Life Sciences industry for more than 20 years. He co-founded Chrysalis Biomedical Advisors after 15+ years in product marketing and business development leadership positions at Applied Biosystems, Agilent Technologies, and Illumina. Rob has worked extensively with customers, commercial and R&D teams to identify, justify, launch and support new products and services across basic and applied markets. Most recently, Rob led a team to design and launch Illumina’s Propel Core Lab certification program, in addition to leading the Actionable Genome Consortium - a high-profile, global effort to define standards for clinical tumor sequencing.
Prior to joining industry, Rob spent two years at Front Line Strategic Management Consulting (now Navigant Consulting) servicing life science and biopharmaceutical clients. Additionally, he spent 4 years as a senior molecular biology technician at UCLA characterizing mouse models of lipid metabolism and running the core lab, and at the University of Wisconsin's McArdle Laboratory for Cancer Research. Rob graduated from the University of Wisconsin-Madison in 1992 with a Bachelor of Science. He earned his MBA from the University of Southern California’s Marshall School of Business in 1999 with a focus in Entrepreneurship and Strategic Human Resource Management. Rob enjoys spending time with his family and playing any sport with a racquet or club.
JORDAN D. STOCKTON, Ph.D.
Partner and Managing Director
Jordan brings a unique mix of technical and commercial experience to the Chrysalis team. Before co-founding Chrysalis Biomedical Advisors, Jordan was Vice President of Marketing at Syapse, serving healthcare providers with enterprise software to deploy and scale precision oncology programs. Previously, Jordan was Director of Marketing for the Enterprise Informatics Business Unit at Illumina where he led commercial efforts to democratize genome-scale sequencing and the analysis of genomic data. In addition, Jordan held the roles of Market Manager for Microarray Gene Expression Products and Platform Manager for Bioinformatics Software at Agilent Technologies. He began his professional career at Silicon Genetics where he launched the GeneSpring software product line, which was foundational in standardizing analytical methods for interpreting microarray data.
Jordan completed his undergraduate studies at Grinnell College. He later received a Ph.D. in chemistry from Georgetown University where he studied the cellular machinery that enables cotranslational protein translocation in the rough endoplasmic reticulum. He enjoys competitive cycling and skiing, and he secretly hopes that his two children will never fully grow up.
DAVID KERN, MBA, RAC
During his 25+ years in the life sciences and medical device industries, Dave has held positions in Product Development, Program Management, Alliance Management, and most recently, Regulatory Affairs. Before starting K2 Regulatory Consulting, Dave was Head of Regulatory Affairs at Illumina, where he also served as the interim Head of Clinical and Medical Affairs. There Dave build a global regulatory organization, with offices in China, Australia, and the UK. He also led the regulatory efforts to bring Illumina their first PMA product approval for the Extended RAS Panel Test in 2017.
Glenn George D.Sc., M.S., MLS (ASCP)
FOCUS: CLINICAL DIAGNOSTIC LABORATORIES
Glenn has been working in the clinical laboratory profession since 2002. He currently is the Director of Clinical Laboratories for a multi-hospital system in Kenosha Wisconsin, a CLIA director for an urgent care center, and a professor of Medical Laboratory Sciences for two University of Wisconsin schools. Glenn also currently works as an independent consultant for clinical laboratories and as expert testimony/advisor in pathology malpractice cases. His research experiences include transcriptional analysis of select agents, characterizations of anti-microbial peptides, and early biomarkers of graft versus host disease for solid tissue transplants.
Michael S. Sherman, MD, MBA, MS
Dr. Michael Sherman serves as chief medical officer and senior vice president for health services for Harvard Pilgrim Health Care, a not-for-profit health plan that has been recognized by NCQA as one of the top health plans in the nation for over a decade. A pioneer in developing outcomes-based payment agreements with pharmaceutical companies that go beyond the historical “pay for pill” approach and tie reimbursement to patient outcomes, he recently signed the first value-based agreement for a gene therapy used to treat a form of blindness.
Jennifer Gardy, Ph.D.
FOCUS: Infectious Disease and Public Health
Dr. Jennifer Gardy holds the Canada Research Chair in Public Health Genomics at the University of British Columbia, and is a pioneer in the field of using next-generation sequencing as a tool to reconstruct outbreaks of infectious disease. Her research lies at the intersection of genomic epidemiology, information visualization, and data science. She is a member of the National Academy of Medicine’s Forum on Microbial Threats, and a scientific advisory board member for both uBiome and Animalbiome.
Adam has extensive experience in developing and commercializing new products, technologies and applications, and has held both commercial and R&D management roles in leading biotechnology companies. Adam was VP of Marketing at Personalis, a leading genomics-based precision medicine company founded by John West, former Solexa CEO. He was VP of Commercial Operations at Oxford Nanopore Technologies, and he built and led Illumina’s product marketing/product management team for next-generation sequencing (NGS).
Before his years at Illumina, Adam served as Director of Scientific Operations at Applied Biosystems (now the Life Technologies division of Thermo Fisher), where he had previously held both scientific and commercial roles. Adam worked in Business Development at Agilent Technologies, and was the Director of Web Products and Executive Producer at Genetic Health, a healthcare startup focused on building on-line tools for risk assessment, management and research on the genetic basis of common disease.